Belén Álvarez-Palomo1,2, Iris García-Martinez3, Jorge Gayoso4, Angel Raya5, Anna Veiga5, María Luisa Abad6, Adolfo Eiras6, María Guzmán-Fulgencio7, Mar Luis-Hidalgo7, Cristina Eguizabal8,9, Silvia Santos8,9, Antonio Balas10, Raquel Alenda10, Francisco Sanchez-Gordo11, Laura Ponce Verdugo11, Juliana Villa12, Enric Carreras12, Francisco Vidal3,13,14, Alejandro Madrigal15,16, María José Herrero3, Francesc Rudilla3, Sergi Querol17,18. 1. Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat 116, 08005, Barcelona, Spain. abalvarez@bst.cat. 2. Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR), Passeig de la Vall d'Hebron 129-139, 08035, Barcelona, Spain. abalvarez@bst.cat. 3. Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat 116, 08005, Barcelona, Spain. 4. Organización Nacional de Trasplantes, Ministerio de Sanidad, C/ Sinesio Delgado 6 - Pabellón 3, 28029, Madrid, Spain. 5. Programa de Medicina Regenerativa, Institut d'Investigació Biomèdica de Bellvitge. IDIBELL, Hospital Duran i Reynals, Gran Via de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. 6. Axencia Galega de Sangue, Órganos e Tecidos, Rúa Xoaquín Díaz de Rábago 2, 15705, Santiago, Spain. 7. Centro de Transfusión de la Comunidad Valenciana, Av. del Cid, 65-acc, 46014, Valencia, Spain. 8. Basque Center for Blood Transfusion and Human Tissues, Barrio Labeaga, s/n, 48960, Galdakao, Spain. 9. Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Células Madre y Tejidos, Cruces Plaza, 48903, Barakaldo, Spain. 10. Centro de Transfusión de la Comunidad de Madrid, Avda. de la Democracia, s/n, 28032, Madrid, Spain. 11. Centro de Transfusión, Tejidos y Células de Málaga, Avda. Doctor Gálvez Ginachero s/n, 29009, Málaga, Spain. 12. REDMO / Fundació i Institut de Recerca Josep Carreras, C/Muntaner, 383 2n, 08021, Barcelona, Spain. 13. Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain. 14. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. 15. Royal Free Hospital, Pond Street, Hampstead, NW3 2QG, UK. 16. UCL Cancer Institute, Medical School, 74 Huntley St, Bloomsbury, London, WC1E 6DE, UK. 17. Banc de Sang i Teixits, Edifici Dr. Frederic Duran i Jordà, Passeig Taulat 116, 08005, Barcelona, Spain. squerol@bst.cat. 18. Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR), Passeig de la Vall d'Hebron 129-139, 08035, Barcelona, Spain. squerol@bst.cat.
Abstract
BACKGROUND: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. METHODS: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. RESULTS: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. CONCLUSION: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.
BACKGROUND: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population. METHODS: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch. RESULTS: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population. CONCLUSION: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.
Authors: Robert C Williams; Gerhard Opelz; Chelsea J McGarvey; E Jennifer Weil; Harini A Chakkera Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: C Alan Howard; Marcelo A Fernandez-Vina; Frederick R Appelbaum; Dennis L Confer; Steven M Devine; Mary M Horowitz; Adam Mendizabal; Ginna G Laport; Marcelo C Pasquini; Stephen R Spellman Journal: Biol Blood Marrow Transplant Date: 2014-09-30 Impact factor: 5.742
Authors: C Eguizabal; B Aran; S M Chuva de Sousa Lopes; M Geens; B Heindryckx; S Panula; M Popovic; R Vassena; A Veiga Journal: Hum Reprod Open Date: 2019-01-29
Authors: Martin W Nicholson; Chien-Yu Ting; Darien Z H Chan; Yu-Che Cheng; Yi-Chan Lee; Ching-Chuan Hsu; Ching-Ying Huang; Patrick C H Hsieh Journal: Cells Date: 2022-06-06 Impact factor: 7.666
Authors: Jonna Clancy; Kati Hyvärinen; Jarmo Ritari; Tiina Wahlfors; Jukka Partanen; Satu Koskela Journal: Stem Cell Res Ther Date: 2022-10-09 Impact factor: 8.079